The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes
Abstract
The aim of this review, after a short presentation of the United Kingdom Prospective Diabetes Study (UKPDS), is to stress that metformin is the drug of choice for overweight type 2 diabetic patients. The effect of metformin on various cardiovascular risk factors is briefly discussed.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.